A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Adrenergic Agonists; Solabegron

Criteria

Inclusion Criteria:

• Subjects with no evidence of current or past history suggestive of gastrointestinal disease or disorder or medical illness that could compromise interpretation of the study.

• no clinically significant laboratory results collected at the screening visit

• men: body weight greater than or equal to 50kg (110 lbs)

• women: body weight greater than or equal to 45kg (100 lbs)

• BMI between 18.5 - 35 kg/m2

Exclusion Criteria:

• Females who are nursing or pregnant.

• history of inflammatory bowel disease

• history of gastric ulcers within 12 months of signing the informed consent form

• tobacco users